|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGEF9 |
Gene summary for ARHGEF9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGEF9 | Gene ID | 23229 |
| Gene name | Cdc42 guanine nucleotide exchange factor 9 | |
| Gene Alias | COLLYBISTIN | |
| Cytomap | Xq11.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | O43307 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23229 | ARHGEF9 | LZE7T | Human | Esophagus | ESCC | 4.52e-03 | 2.41e-01 | 0.0667 |
| 23229 | ARHGEF9 | LZE8T | Human | Esophagus | ESCC | 1.37e-03 | 1.07e-01 | 0.067 |
| 23229 | ARHGEF9 | LZE24T | Human | Esophagus | ESCC | 6.30e-08 | 1.87e-01 | 0.0596 |
| 23229 | ARHGEF9 | P1T-E | Human | Esophagus | ESCC | 2.18e-09 | 4.06e-01 | 0.0875 |
| 23229 | ARHGEF9 | P2T-E | Human | Esophagus | ESCC | 2.40e-09 | 1.76e-01 | 0.1177 |
| 23229 | ARHGEF9 | P4T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.78e-01 | 0.1323 |
| 23229 | ARHGEF9 | P5T-E | Human | Esophagus | ESCC | 1.42e-11 | 2.15e-01 | 0.1327 |
| 23229 | ARHGEF9 | P8T-E | Human | Esophagus | ESCC | 1.68e-13 | 2.13e-01 | 0.0889 |
| 23229 | ARHGEF9 | P10T-E | Human | Esophagus | ESCC | 4.58e-18 | 2.72e-01 | 0.116 |
| 23229 | ARHGEF9 | P12T-E | Human | Esophagus | ESCC | 8.29e-12 | 2.10e-01 | 0.1122 |
| 23229 | ARHGEF9 | P16T-E | Human | Esophagus | ESCC | 1.35e-26 | 5.42e-01 | 0.1153 |
| 23229 | ARHGEF9 | P19T-E | Human | Esophagus | ESCC | 6.73e-05 | 2.57e-01 | 0.1662 |
| 23229 | ARHGEF9 | P20T-E | Human | Esophagus | ESCC | 1.68e-08 | 2.13e-01 | 0.1124 |
| 23229 | ARHGEF9 | P21T-E | Human | Esophagus | ESCC | 3.75e-03 | 5.99e-02 | 0.1617 |
| 23229 | ARHGEF9 | P22T-E | Human | Esophagus | ESCC | 4.70e-25 | 3.43e-01 | 0.1236 |
| 23229 | ARHGEF9 | P24T-E | Human | Esophagus | ESCC | 3.40e-07 | 1.24e-01 | 0.1287 |
| 23229 | ARHGEF9 | P26T-E | Human | Esophagus | ESCC | 2.82e-17 | 3.13e-01 | 0.1276 |
| 23229 | ARHGEF9 | P27T-E | Human | Esophagus | ESCC | 2.04e-02 | 4.36e-02 | 0.1055 |
| 23229 | ARHGEF9 | P28T-E | Human | Esophagus | ESCC | 1.32e-06 | 1.42e-01 | 0.1149 |
| 23229 | ARHGEF9 | P30T-E | Human | Esophagus | ESCC | 1.34e-05 | 2.17e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005105610 | Esophagus | ESCC | regulation of small GTPase mediated signal transduction | 157/8552 | 302/18723 | 1.55e-02 | 4.98e-02 | 157 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGEF9 | SNV | Missense_Mutation | c.22N>A | p.Asp8Asn | p.D8N | O43307 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ARHGEF9 | SNV | Missense_Mutation | c.1005N>A | p.Asn335Lys | p.N335K | O43307 | protein_coding | tolerated(0.09) | benign(0.066) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARHGEF9 | SNV | Missense_Mutation | novel | c.818N>T | p.Ala273Val | p.A273V | O43307 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| ARHGEF9 | SNV | Missense_Mutation | c.457N>A | p.Glu153Lys | p.E153K | O43307 | protein_coding | deleterious(0.02) | possibly_damaging(0.866) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| ARHGEF9 | SNV | Missense_Mutation | c.1129N>A | p.Glu377Lys | p.E377K | O43307 | protein_coding | tolerated(0.12) | benign(0.059) | TCGA-BH-A201-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARHGEF9 | SNV | Missense_Mutation | rs781823638 | c.145N>A | p.Gln49Lys | p.Q49K | O43307 | protein_coding | tolerated(0.1) | benign(0.05) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| ARHGEF9 | SNV | Missense_Mutation | novel | c.283N>T | p.Arg95Trp | p.R95W | O43307 | protein_coding | tolerated(0.12) | benign(0.393) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ARHGEF9 | SNV | Missense_Mutation | c.757N>A | p.Leu253Met | p.L253M | O43307 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| ARHGEF9 | SNV | Missense_Mutation | novel | c.464N>G | p.Ile155Ser | p.I155S | O43307 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ARHGEF9 | SNV | Missense_Mutation | novel | c.154G>A | p.Asp52Asn | p.D52N | O43307 | protein_coding | deleterious(0.04) | possibly_damaging(0.691) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |